1004316-93-1

Basic information

• Product Name: 3-methyl-1-[(3S)-2-oxooxolan-3-yl]-3-{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}urea
• Synonyms: 3-methyl-1-[(3S)-2-oxooxolan-3-yl]-3-{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}urea
• CAS NO: 1004316-93-1
• Molecular Formula: C₁₃H₁₉N₃O₃S
• Molecular Weight: 297.37326
• Mol File: 1004316-93-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 564.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• PKA: 12.30±0.20(Predicted)
• CAS DataBase Reference: 3-methyl-1-[(3S)-2-oxooxolan-3-yl]-3-{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}urea(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-1-[(3S)-2-oxooxolan-3-yl]-3-{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}urea(1004316-93-1)
• EPA Substance Registry System: 3-methyl-1-[(3S)-2-oxooxolan-3-yl]-3-{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}urea(1004316-93-1)

Safety Data

• Hazardous Substances Data: 1004316-93-1(Hazardous Substances Data)

Upstream product

• 530-62-1 1,1'-carbonyldiimidazole 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 2185-02-6 L-homoserine lactone 
• 6305-38-0 (S)-(-)-α-amino-γ-butyrolactone hydrobromide 
• 154212-60-9 N-methyl-N-<(2-isopropyl-4-thiazolyl)methyl>amine 

Downstream Products

• 1169870-28-3 C₃₆H₅₃N₇O₅S₂ 
• 1169870-18-1 C₃₉H₅₁N₇O₅S₂ 
• 1004316-94-2 C₂₀H₂₇N₃O₄S 
• 1247119-36-3 (S)-ethyl-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanoate oxalate 
• 1169870-16-9 C₁₇H₂₇N₄O₄S^(1-)*K⁽¹⁺⁾ 
• 1004316-96-4 C₂₄H₃₄N₄O₄S 
• 1004316-95-3 C₂₀H₂₅N₃O₄S 
• 1004316-92-0 C₁₇H₂₈N₄O₄S 
• 1004316-87-3 C₃₆H₄₇N₇O₄S₂ 

Relevant articles and documents

NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R,5R)-5- CARBAMOYL) AMINO] -4-(MORPHOLIN-4-YL)BUTANOYL]AMINO}-1,6-DIPHENYLHEXAN-2-YL]CARBAMATE

The present invention relates to novel processes for the preparation 1,3-Thiazol-5-ylmethyl[(2R,5R)-5-{[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl} carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl] carbamate having the following structural formula-1 and it's intermediates thereof.

INHIBITORS OF CYTOCHROME P450

The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.

PROCESS FOR THE PREPARATION OF COBICISTAT INTERMEDIATES

The present invention relates to cobicistat intermediates, processes and further conversion to cobicistat with improved yield and quality.